商品介绍
Description:EndoCab®,Human,ELISAkit
TheEndoCab®ELISAhasbeendevelopedfordeterminationofendotoxincoreantibodiesinhumanplasmaorseruminpatientsorhealthyindividuals.Severalstudiesshowaconsistentdropinpostoperativelevelsofcirculatinganti-endotoxincoreantibodiesfromthepreoperativevalue.Thisdrophasbeeninterpretedasconsumptionofantibodiestoendotoxinbysystemicreleaseofendotoxin.Ahypothesisisthatifthepatientspre-operativeEndoCab®levelislow,evenmoderatelylow,patientsmaynotbeabletocopewiththeeffluxofendotoxin,whichmayhavemildtosevereclinicalconsequences.TheassayisofinterestforvariousexperimentalconditionsrangingfrominvitroLPSneutralizationbyplasmacomponentstoinvivostudiesonkineticsofantibodiestoendotoxininhealthanddiseases.TheEndoCab®standardmedian-unitsIgG,IgMandIgA(MU)arearbitraryandarebasedonmediansofrangesfor1000healthyadultsinaparticularlocality.IthasnotbeenestablishedwhethernormalEndoCab®valuesvarybyregion,cultureorrace.Usersshouldestablishappropriatelocalstatisticalcontrolsfortheirstudies.Itisadvisedthatstudiesofanypatientgroupshouldalwaysbecontrolledbystudiesofappropriatelyselectedcontrastingclinicalgroupsand/orhealthyindividualsrecruitedlocally.EndoCab®isaregisteredtrademark.UsedunderlicensefromtheScottishNationalBloodTransfusionService.
Specifications:
| Catalognumber | HK504 |
|---|---|
| Producttype | Assays |
| Quantity | 1x96det. |
| Standardrange | StandardcurveofIgGfrom0.13‑8GMU/ml.StandardcurveofIgMfrom0.05-3.5MMU/ml.StandardcurveofIgAfrom0.16-10AMU/ml. |
| Detectionlevel | MinimumdetectionlevelIgGEndoCab®antibodiesis0.13GMU/ml.MinimumdetectionlevelIgMEndoCab®antibodiesis0.05MMU/ml.MinimumdetectionlevelIgAEndoCab®antibodiesis0.16AMU/ml. |
| Workingvolume | 100µl/well |
| Species | Human |
| Application | TheEndoCab®ELISAkitistobeusedfortheinvitroquantitativedeterminationofendotoxincoreantibodiesinserum,plasmaandcellculturesupernatant. |
| Disease | Gastroenterology,Infectiousdiseases |
| Principle | TheEndoCab®ELISAisaready-to-usesolid-phaseenzyme-linkedimmunosorbentassaybasedonthesandwichprinciplewithaworkingtimeof2½hours.Theefficientformatof1platewithtwelvedisposable8-wellstripsallowsfreechoiceofbatchsizefortheassay.Samplesandstandardsareincubatedinmicrotiterwellscoatedwithequimolaramountsofendotoxinrough-lipopolysaccharidesfromfourGram-negativebacterialspecies,eachcomprisedofacompleteinnercore,butlackingcompleteoutercoreorO-specificpolysaccharidechain.Theseendotoxins,complexedwithpolymyxinB,constitutethesolidphaseantigen.Duringthisincubationanti-endotoxin-coreantibodiesarecapturedbythesolidphaseantigen.Unboundmaterialpresentinthesampleisremovedbywashing.Peroxidaseconjugatedanti-humanIg(GorMorA)tracerantibodyisaddedtothewells.IfEndoCabantibodieswerepresentinthesample,tracerantibodieswillbindtothecapturedEndoCabantibodies.Excesstracerisremovedbywashingandsubstrate,tetramethylbenzidine(TMB),isaddedtothewells.Colordevelopsproportionallytotheamountofantiendotoxincoreantibodiespresentinthesample.Theenzymereactionisstoppedbytheadditionofcitricacid.Theabsorbanceat450nmismeasuredwithaspectrophotometer.Astandardcurveisobtainedbyplottingtheabsorbance(linear)versusthecorrespondingconcentrationsoftheLBPstandards(log).ThehumanEndoCab®antibodyconcentrationofsamples,whicharerunconcurrentlywiththehumanLBPstandards,canbedeterminedfromthehumanLBPstandardcurve. |
| StorageandstABIlity | Productshouldbestoredat4°C.Underrecommendedstorageconditions,productisstableforoneyear. |
| Precautions | Forresearchuseonly.Notforuseinoronhumansoranimalsorfordiagnostics.Itistheresponsibilityoftheusertocomplywithalllocal/stateandFederalrulesintheuseofthisproduct.HycultBiotechisnotresponsIBLeforanypatentinfringementsthatmightresultwiththeuseoforderivationofthisproduct. |
| References | 1.Barclay,GR;Endogenousendotoxin-coreantibody(EndoCab)asaMarkerofendotoxinexposureandaprognosticindicator:areview.ProgClinBiolRes1995,392:263 2.Allan,Eetal;Anti-bacteroideslipopolysaccharideIgGlevelsinhealthyadultsandsepsispatients.ImmunolMedMicrobiol1995,11:115 3.Barclay,GR,Antibodiestoendotoxininhealthanddisease.RevMedMidrobiol1990,1:133 4.Rahman,Setal;Intestinalhypoperfusioncontributestogutbarrierfailureinsevereacutepancreatitis.JGastrointestSurg2003,7:26 5.Eckerwall,Getal;Earlynasogastricfeedinginpredictedsevereacutepancreatitis:Aclinical,randomizedstudy.AnnSurg2006,244:959 |
品牌介绍
Hycult Biotech 是一家专注于设计、研发、生产以及销售抗体和其相关产品的公司，其特色产品是天然免疫及相关领域的免疫分析试剂，例如补体， 嗜中性粒细胞蛋白，TLP，清道夫受体以及急性期蛋白等。除此之外，Hycult Biotech公司也可以提供炎症反应和细胞损伤等方面的产品。
Hycult Biotech的宗旨和策略是着重于天然免疫相关疾病的研究，为人类生活质量的提高谋福利。作为免疫学和细胞生物学领域的领导者，Hycult Biotech公司不仅研发这些用于生物科学研究的产品，同时也致力于将这些科研产品转化为临床测试的研究。该公司与40多家主要的国际研究机构有着紧密的合作，因此，他们可以持续提供多种创新型试剂。Hycult Biotech公司在1988年就已经获得ISO-9001质量验证，2007年获得ISO-13485验证，2009年获得CE质量认证。Hycult Biotech公司凭借其先进的理念，高效的研究团队以及严格的质监系统为广大科研工作者提供高质量的产品及周到的技术服务。
公司介绍
产品分类
销售排行
厂家直采
全球直采 正品优价
正品保障
厂家直发 有线跟踪
正规清关
CIF100%正规报关，提供发票
及时交付
限时必达 不达必赔
总部地址：
江苏省苏州市工业园区星湖街218号 苏州生物医药产业园一期（生物纳米园）A4-216(邮编：215125)
工作时间：周一至周五9:00~18:00
技术支持：
短信：18915418616
服务热线：
4000-520-616（全国）
☏ 0512-67156496（苏州）
版权信息：
© 2015- 苏州蚂蚁淘生物科技有限公司 版权所有 中国
友情链接：
联系QQ:764052152
免责声明：
本站有部分内容来自互联网，如无意中侵犯了某个媒体 、公司 、企业或个人等的知识产权，请来电或致函告之，
本网站将在规定时间内给予删除等相关处理。
本网站将在规定时间内给予删除等相关处理。
扫描二维码关注官方微信
获取最新促销及产品信息